CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
744.00
-13.00 (-1.72%)
Apr 17, 2026, 3:30 PM JST
Market Cap14.22B -25.7%
Revenue (ttm)n/a
Net Income-1.25B
EPS-63.94
Shares Out19.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume123,600
Average Volume131,920
Open750.00
Previous Close757.00
Day's Range737.00 - 756.00
52-Week Range685.00 - 1,558.00
Beta-0.84
RSI46.05
Earnings DateMay 14, 2026

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 14
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements